Latest News by Industry
MARSEILLE, France--(BUSINESS WIRE)--Sep 15, 2022--
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today reported its consolidated financial results for the six months ended June 30, 2022. The consolidated financial statements are attached to this press release.
“Based on our strong financial position, we continued the momentum in our product pipeline during the second quarter of the year. We are advancing our anti-CD39 blocking monoclonal antibody IPH5201 to a Phase 2 clinical trial in lung cancer with AstraZeneca, and Sanofi selected a second asset for development, targeting BCMA, that benefits from ANKET TM, Innate’s proprietary multi-specific NK cell engager platform and Sanofi’s CROSSDILES ® platform. The ANKET TM technology is the engine for development of our robust pipeline of much needed novel solutions to treat cancer.” said Mondher Mahjoubi, Chief Executive Officer of Innate Pharma. “We continue to see progress for monalizumab in the early non-small cell lung cancer setting, with the ongoing PACIFIC-9 Phase 3 study, sponsored by AstraZeneca, and recent Phase 2 data presentations. We look forward to further clinical readouts from the Phase 2 TELLOMAK trial for lacutamab and ANKET TM updates in the second half of the year.”
Webcast and conference call will be held today at 2:00 p.m. CEST (8:00 a.m. ET) |
Access to live webcast: |
https://event.on24.com/wcc/r/3824660/86089F900A17B3EA55F4BEE49AD268A8 |
|
Participants may also join via telephone by registering in advance of the event at |
|
Upon registration, participants will be provided with dial-in numbers, a direct event passcode and |
a unique registrant ID that they may use 10 minutes prior to the event start to access the call. |
|
This information can also be found on the Investors section of the Innate Pharma website, www.innate-pharma.com. |
A replay of the webcast will be available on the Company website for 90 days following the event. |
Pipeline highlights:
Lacutamab (anti-KIR3DL2 antibody):
ANKET™ (Antibody-based NK cell Engager Therapeutics):
Monalizumab (anti-NKG2A antibody), partnered with AstraZeneca:
IPH5201 (anti-CD39), partnered with AstraZeneca:
IPH5301 (anti-CD73):
Preclinical updates:
Corporate Update:
Financial highlights for the first half of 2022:
The key elements of Innate’s financial position and financial results as of and for the six-month period ended June 30, 2022 are as follows:
Government funding for research expenditures of €4.3m in the first half of 2022 (€6.4m in the first half of 2021).
The table below summarizes the IFRS consolidated financial statements as of and for the six months ended June 30, 2022, including 2021 comparative information.
In thousands of euros, except for data per share | June 30, 2022 | June 30, 2021 | ||
Revenue and other income | 45,589 | 14,671 | ||
Research and development expenses | (24,956) | (21,208) | ||
General and administrative expenses | (12,140) | (12,643) | ||
Operating expenses | (37,096) | (33,851) | ||
Operating income (loss) | 8,494 | (19,179) | ||
Net financial income (loss) | (2,118) | 1,709 | ||
Income tax expense | — | — | ||
Net income (loss) from continuing operations | 6,376 | (17,470) | ||
Net income (loss) from discontinued operations | (73) | (6,249) | ||
Net income (loss) | 6,303 | (23,719) | ||
Weighted average number of shares ( in thousands) : | 79,754 | 78,998 | ||
- Basic income (loss) per share | 0.08 | (0.30) | ||
- Diluted income (loss) per share | 0.08 | (0.30) | ||
-Basic income (loss) per share from continuing operations | 0.08 | (0.22) | ||
- Diluted income (loss) per share from continuing operations | 0.08 | (0.22) | ||
-Basic income (loss) per share from discontinued operations | — | (0.08) | ||
- Diluted income (loss) per share from discontinued operations | — | (0.08) |
(1) Comparative relating to the six months ended June 30, 2021 have been restated to reflect the impact of the classification of Lumoxiti's activities as discontinued operations in 2021. |
| June 30, 2022 | December 31, | ||
Cash, cash equivalents and financial assets | 158,156 | 159,714 | ||
Total assets | 280,430 | 267,496 | ||
Total shareholders’ equity | 116,333 | 107,440 | ||
Total financial debt | 43,374 | 44,251 |
About Innate Pharma:
Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.
Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.
Innate is a pioneer in the understanding of Natural Killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.
Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.
Learn more about Innate Pharma at www.innate-pharma.com
Information about Innate Pharma shares:
ISIN code | FR0010331421 | |||
Ticker code | Euronext: IPH Nasdaq: IPHA | |||
LEI | 9695002Y8420ZB8HJE29 |
Disclaimer on forward-looking information and risk factors:
This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts, the Company’s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company’s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2021, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
Summary of Interim Condensed Consolidated Financial Statements and Notes as of JUNE 30, 2022
Interim Condensed Consolidated Statements of Financial Position | ||||
(in thousand euros) | ||||
| June 30, 2022 | December 31, 2021 | ||
Assets |
|
| ||
|
|
| ||
Current assets |
|
| ||
Cash and cash equivalents | 102,949 | 103,756 | ||
Short-term investments | 20,401 | 16,080 | ||
Trade receivables and others | 48,447 | 18,420 | ||
Total current assets | 171,797 | 138,256 | ||
|
|
| ||
Non-current assets |
|
| ||
Intangible assets | 43,260 | 44,192 | ||
Property and equipment | 9,556 | 10,174 | ||
Non-current financial assets | 34,806 | 39,878 | ||
Other non-current assets | 149 | 148 | ||
Trade receivables and others - non-current | 13,084 | 29,821 | ||
Deferred tax asset | 7,778 | 5,028 | ||
Total non-current assets | 108,633 | 129,241 | ||
|
|
| ||
Total assets | 280,430 | 267,496 | ||
Liabilities |
|
| ||
|
|
| ||
Current liabilities |
|
| ||
Trade payables and others | 18,667 | 28,573 | ||
Collaboration liabilities – current portion | 14,167 | 7,418 | ||
Financial liabilities – current portion | 30,851 | 30,748 | ||
Deferred revenue – current portion | 9,094 | 12,500 | ||
Provisions - current portion | 782 | 647 | ||
Total current liabilities | 73,561 | 79,886 | ||
|
|
| ||
Non-current liabilities |
|
| ||
Collaboration liabilities – non-current portion | 58,954 | 32,997 | ||
Financial liabilities – non-current portion | 12,523 | 13,503 | ||
Defined benefit obligations | 2,696 | 2,975 | ||
Deferred revenue – non-current portion | 8,333 | 25,413 | ||
Provisions - non-current portion | 253 | 253 | ||
Deferred tax liabilities | 7,778 | 5,028 | ||
Total non-current liabilities | 90,537 | 80,169 | ||
|
|
| ||
Shareholders’ equity |
|
| ||
Share capital | 3,988 | 3,978 | ||
Share premium | 377,998 | 375,220 | ||
Retained earnings | (272,241) | (219,404) | ||
Other reserves | 284 | 456 | ||
Net income (loss) | 6,303 | (52,809) | ||
Total shareholders’ equity | 116,333 | 107,440 | ||
|
|
| ||
Total liabilities and shareholders’ equity | 280,430 | 267,496 |
Interim Condensed Consolidated Statements of Income (loss) | |||
(in thousand euros) | |||
| June 30, 2022 | June 30, 2021 (1) | |
|
|
| |
Revenue from collaboration and licensing agreements | 41,271 | 8,304 | |
Government financing for research expenditures | 4,319 | 6,368 | |
|
|
| |
Revenue and other income | 45,589 | 14,671 | |
|
|
| |
Research and development expenses | (24,956) | (21,208) | |
General and administrative expenses | (12,140) | (12,643) | |
|
|
| |
Operating expenses | (37,096) | (33,851) | |
|
|
| |
Net income / (loss) distribution agreements | — | — | |
|
|
| |
Operating income (loss) | 8,494 | (19,179) | |
|
|
| |
Financial income | 4,048 | 3,490 | |
Financial expenses | (6,166) | (1,781) | |
|
|
| |
Net financial income (loss) | (2,118) | 1,709 | |
|
|
| |
Net income (loss) before tax | 6,376 | (17,470) | |
|
|
| |
Income tax expense | — | — | |
|
|
| |
Net income (loss) from continuing operations | 6,376 | (17,470) | |
|
|
| |
Net income (loss) from discontinued operations | (73) | (6,249) | |
|
|
| |
Net income (loss) | 6,303 | (23,719) | |
|
|
| |
Weighted average number of shares : (in thousands) | 79,754 | 78,998 | |
- Basic income (loss) per share | 0.08 | (0.30) | |
- Diluted income (loss) per share | 0.08 | (0.30) | |
-Basic income (loss) per share from continuing operations | 0.08 | (0.22) | |
- Diluted income (loss) per share from continuing operations | 0.08 | (0.22) | |
-Basic income (loss) per share from discontinued operations | — | (0.08) | |
- Diluted income (loss) per share from discontinued operations | — | (0.08) |
(1) Comparative relating to the six months ended June 30, 2021 have been restated to reflect the impact of the classification of Lumoxiti's activities as discontinued operations in 2021. |
Interim Condensed Consolidated Statements of Cash Flow | ||||
(in thousand euros) | ||||
| June 30, 2022 | June 30, 2021 | ||
Net income (loss) | 6,303 | (23,719) | ||
Depreciation and amortization, net | 2,030 | 2,168 | ||
Employee benefits costs | 192 | 268 | ||
Change in provision for charges | 134 | 4,952 | ||
Share-based compensation expense | 2,596 | 853 | ||
Change in valuation allowance on financial assets | 2,255 | (1,031) | ||
Gains (losses) on financial assets | (1,333) | (443) | ||
Change in valuation allowance on financial instruments | (100) | (170) | ||
Gains on assets and other financial assets | (25) | (86) | ||
Interest paid | 194 | 160 | ||
Other profit or loss items with no cash effect | (52) | (1,476) | ||
Operating cash flow before change in working capital | 12,194 | (18,524) | ||
Change in working capital | (10,976) | (12,638) | ||
Net cash generated from / (used in) operating activities: | 1,218 | (31,162) | ||
Acquisition of intangible assets, net | — | (33) | ||
Acquisition of property and equipment, net | (420) | (240) | ||
Purchase of non-current financial instruments | — | — | ||
Disposal of property and equipment | — | 2 | ||
Purchase of other assets | (1) | (63) | ||
Interest received on financial assets | 25 | 86 | ||
Net cash generated from / (used in) investing activities: | (395) | (247) | ||
Proceeds from the exercise / subscription of equity instruments | 192 | 61 | ||
Repayment of borrowings | (958) | (1,127) | ||
Net interest paid | (194) | (160) | ||
Net cash generated / (used in) from financing activities: | (960) | (1,226) | ||
Effect of the exchange rate changes | (670) | (178) | ||
Net increase / (decrease) in cash and cash equivalents: | (807) | (32,812) | ||
Cash and cash equivalents at the beginning of the year: | 103,756 | 136,792 | ||
Cash and cash equivalents at the end of the six-months period: | 102,949 | 103,980 |
Revenue and other income
The following table summarizes operating revenue for the periods under review:
In thousands of euros | June 30, 2022 | June 30, 2021 (1) | ||
Revenue from collaboration and licensing agreements | 41,271 | 8,304 | ||
Government funding for research expenditures | 4,319 | 6,368 | ||
Revenue and other income | 45,589 | 14,671 |
(1) Comparative relating to the six months ended June 30, 2021 have been restated to reflect the impact of the classification of Lumoxiti's activities as discontinued operations in 2021. |
Revenue from collaboration and licensing agreements
Revenue from collaboration and licensing agreements increased by €33.0 million, to €41.3 million for the six months ended June 30, 2022, as compared to revenues from collaboration and licensing agreements of €8.3 million for the six months ended June 30, 2021. These revenues mainly result from the partial or entire recognition of the proceeds received pursuant to the agreements with AstraZeneca and Sanofi and which are recognized on the basis of the percentage of completion of the works performed by the Company under such agreements.
The evolution for the first half of 2022 is mainly due to:
Government funding for research expenditures
Government financing for research expenditures decreased by €2.0 million, or 32.2%, to €4.3 million for the six months ended June 30, 2022 as compared to €6.4 million the six months ended June 30, 2021. This change is primarily a result of a decrease in the research tax credit (CIR) of €0.7 million, which is mainly due to (i) a decrease in eligible subcontracting costs included in research tax credit calculation, in connection with the end of the doubling of public subcontracting expenses eligible for the CIR since January 1, 2022, but also to the decrease in private R&D subcontracting over the period due to the maturity of clinical trials. In addition, this decrease is also explained by the deduction from the CIR calculation base of the remaining financing received over the period relating to FORCE (FOR COVID-19 Elimination) trial ; (ii) in addition, there is a €1.4 million decrease in grants in connection with the recording in revenue in the first half of 2021 of the first tranche of the repayable advance paid to the Company and linked to the BPI financing contract signed in August 2020. This payment was received by the Company at contract signing. This financing contract was set up as part of the program set up by the French government to help develop a therapeutic solution with a preventive or curative aim against COVID-19. As of June 30, 2021, this financing was considered by the Company to be non-refundable , in accordance with the terms of the agreement, in light of the technical and commercial failure of the project based on the results of the Phase 2 "Force" trial evaluating avdoralimab in COVID-19, published on July 6, 2021.
The Company is again eligible to the SME status under European Union criteria since December 31, 2021. Consecutively, the Company is eligible for the early repayment by French treasury of the 2021 research tax credit during the fiscal year 2022.
Operating expenses
The table below presents our operating expenses from continuing operations for the six months periods ended June 30, 2022 and 2021:
In thousands of euros | June 30, 2022 | June 30, 2021 (1) | ||
Research and development expenses | (24,956) | (21,208) | ||
General and administrative expenses | (12,140) | (12,643) | ||
Operating expenses | (37,096) | (33,851) |
(1) Comparative relating to the six months ended June 30, 2021 have been restated to reflect the impact of the classification of Lumoxiti's activities as discontinued operations in 2021. |
Research and development expenses
Research and development (“R&D”) expenses from continuing operations increased by €3.7 million, or 17.7%, to €25.0 million for the six months ended June 30, 2022, as compared to €21.2 million for the six months ended June 30, 2021, representing a total of 67.3% and 62.7% of the total operating expenses, respectively. R&D expenses include direct R&D expenses (subcontracting costs and consumables), depreciation and amortization, and personnel expenses.
Direct R&D expenses increased by €0.7 million, or 5.9%, to €12.4 million for the six months ended June 30, 2022, as compared to €11.7 million for the six months ended June 30, 2021. This increase is mainly explained by (i) an increase of 1.7 million euros in expenses relating to the lacutamab program as well as (ii) an increase of 1.4 million euros in expenses relating to the IPH65 preclinical program partially offset by (iii) the decrease expenses related to the avdoralimab and monalizumab programs for respectively 1.8 million euros and 0.7 million euros. These decreases follow (i) the decision taken by the Company at the end of the first half of 2020 to stop recruitment in trials evaluating avdoralimab in oncology and (ii) the maturity of phase I/II clinical trials entering the scope of the collaboration with AstraZeneca regarding monalizumab.
Also, as of June 30, 2022, the collaboration liabilities relating to monalizumab and the agreements signed with AstraZeneca in April 2015, October 2018 and September 2020 amounted to €73.1 million, as compared to collaborations liabilities to €40.4 million as of December 31, 2021. This increase of €32.7 million mainly results from (i) the increase in the collaboration commitment for an amount of €34.3 million ($36.0 million USD) in connection with the launch of the PACIFIC-9 Phase 3 trial by AstraZeneca on April 28, 2022, and (ii) the increase in the collaboration commitment in the amount of €3.7 million in connection with the observed exchange rate fluctuations over the period for the euro-dollar parity, partially offset by (iii) net reimbursements of €5.0 million made in the first half of 2022 to AstraZeneca relating to the co-financing of the monalizumab program, mainly including the Phase 3 INTERLINK-1 trial launched in October 2020.
Personnel and other expenses allocated to R&D increased by €3.1 million, or 32.1%, to €12.6 million for the six months ended June 30, 2022, as compared to an amount of €9.5 million for the six months ended June 30, 2021. This increase is mainly due to (i) the increase of €1.7 million in personnel expenses allocated to research and development, of which €1.1 million related to share-based payments (implementation of an employee savings plan remunerated in free shares in particular) and (ii) the increase of €1.6 million in other expenses allocated to research and development in particular in connection with (a) the provision for charges in the amount of €0.6 million expensed in respect of the payment to be issued to the Company Orega Biotech SAS upon receipt of the milestone payment of $5.0m from AstraZeneca, following the signature on June 1, 2022 of an amendment to the initial IPH5201 contract signed in October 2018 and (b) the increase of €0.6 million in non-scientific fees allocated to research and development in view of an increase in the use of external service providers in the first half of 2022.
General and administrative expenses
General and administrative expenses from continuing activities decreased by €0.5 million, or 4.0%, to €12.1 million for the six months ended June 30, 2022, as compared to general and administrative expenses of €12.6 million for the six months ended June 30, 2021. Selling, general and administrative expenses represented a total of 32.7% and 37.3% of the total operating expenses for the six months ended June 30, 2022 and 2021, respectively.
Personnel expense includes the compensation paid to our employees, and increased by €0.6 million, to €5.8 million for the six months ended June 30, 2022, as compared to €5.2 million for six months ended June 30, 2021. This increase of €0.6 million is mainly due to the increase in share-based payments, in particular in connection with the implementation of an employee savings plan paid in bonus shares.
Non-scientific advisory and consulting expenses mostly consist of auditing, accounting, taxation and legal fees as well as consulting fees in relation to business strategy and operations and hiring services. Non-scientific advisory and consulting expenses decreased by €0.3 million, or 10.4%, to €2.2 million for the six months ended June 30, 2022 as compared to €2.5 million for the six months ended June 30, 2021. This decrease is mainly due to the decrease in fees in connection with (i) the services of lawyers relating to the arbitration procedure between the Company and Orega Biotech concerning the joint ownership of certain patents relating to IPH5201, settled at the end of 2021 and (ii) the services provided in 2021 as part of support for the application of internal control standards in connection with the Sarbanes-Oxley Act following the Nasdaq listing of the Company in October 2019.
The fall in other expenses of €0.8m mainly results from non recurring provisions for liabilities and charges booked in the 1st half of 2021 reversed in 1st half of 2022.
Financial income (loss), net
We recognized a net financial loss of €2.1 million in the six months ended June 30, 2022 as compared to a net financial gain of €1.7 million in the six months ended June 30, 2021. This variance mainly results from the variance in fair value of our financial instruments (net gain of €1.0 million as compared to a net loss of €2.3 million for the six months ended June 30, 2021 and 2022, respectively). The decline in the fair value of our financial instruments observed in the first half of 2022 results from the impact of the COVID-19 health crisis as well as the Ukrainian crisis on the financial markets.
Net loss from discontinued operations
As a reminder, further to the decision to terminate the Lumoxiti Agreement and termination notice sent in December 2020, a Termination and Transition Agreement was discussed and executed, effective as of June 30, 2021 terminating the Lumoxiti Agreement as well as Lumoxiti related agreements (including the supply agreement, the quality agreement and other related agreements) and transferring of the U.S. marketing authorization and distribution rights of Lumoxiti back to AstraZeneca. Consecutively, the activities related to Lumoxiti are presented as a discontinued operation as of October 1, 2021 (and for all subsequent and prior period).
As a consequence, net loss from discontinued operations relating to Lumoxiti for the six months ended June 30 2022, decreased by €6.2m as compared to net loss from discontinued operations for the six months ended June 30, 2021. Net loss for the six months ended June 30, 2021 mainly resulted from the Settlement Amount of $6.2m (€5.2m as of June 30, 2021) to be paid to AstraZeneca on April 30, 2022, as part of the Termination and Transition agreement.
Balance sheet items
Cash, cash equivalents, short-term investments and non-current financial assets amounted to €158.2 million as of June 30, 2022, as compared to €159.7 million as of December 31, 2021. Net cash as of June 30, 2022 amounted to €92.5 million (€89.1 million as of December 31, 2021). Net cash is equal to cash, cash equivalents and short-term investments less current financial liabilities.
The other key balance sheet items as of June 30, 2022 are:
Cash-flow items
As of June 30, 2022, cash and cash equivalents amounted to €102.9 million, compared to €103.8 million as of December 31, 2021, corresponding in a decrease of €0.8 million.
The net cash flow used during the period under review mainly results from the following:
Post period events
On August 1, 2022, the Company announced that the combination of monalizumab and cetuximab did not reach the pre-specified efficacy threshold in the protocol-planned interim futility analysis of the Phase 3 INTERLINK-1 clinical study conducted by AstraZeneca. AstraZaneca has thus informed the Company that the study will be discontinued. Consequently, the Company is not eligible for the additional payment of $50.0 million as provided for in the amendment signed in September 2020 relating to the monzalizumab collaboration and license agreement entered into with AstraZeneca in 2015. All other development and commercial milestone payments related to the agreement remain unchanged.
In August 2022, the Company communicated to Société Générale and BNP Paribas its desire to use the capital repayment extension options of the two State-Guaranteed Loans (“PGE”) contracted in December 2021. As a reminder, the Company had obtained non-dilutive financing of 28.7 million in the form of two PGEs from Société Générale (20.0 million euros) and BNP Paribas (8.7 million euros) with a maturity initial of one year with an option to extend up to five years. Discussions are currently underway with Société Générale and BNP Paribas regarding the conditions for extending repayment and the effective interest rate of loans. At the date of this report, the Company has obtained agreements in principle from Société Générale and BNP Paribas concerning financing rates after extension option of 1.56% and 0.95% respectively, excluding insurance and guarantee premium with an excess for the whole of 2023.
Nota
The interim consolidated financial statements for the six-month period ended June 30, 2022 have been subject to a limited review by our Statutory Auditors and were approved by the Executive Board of the Company on September 14, 2022. They were reviewed by the Supervisory Board of the Company on September 14, 2022. They will not be submitted for approval to the general meeting of shareholders.
Risk factors
Risk factors identified by the Company are presented in section 3 of the universal registration document (“Document d’Enregistrement Universel”) submitted to the French stock-market regulator, the “Autorité des Marchés Financiers”, on April 4, 2022 (AMF number D.22-0234). The main risks and uncertainties the Company may face in the six remaining months of the year are the same as the ones presented in the universal registration document available on the internet website of the Company.
Furthermore, the conflict triggered by Russia's invasion of Ukraine on February 24, 2022 had no significant direct or indirect consequences on the Company's interim consolidated financial statements for the first half of 2022. An update of that risk is presented in note G) of the half-year management review as of June 30, 2022. The risks that are likely to arise during the remaining six months of the current financial year could also occur during subsequent years.
Related party transactions:
Transactions with related parties during the periods under review are disclosed in Note 19 to the interim condensed consolidated financial statements for the period ended June 30, 2022 prepared in accordance with IAS 34.
| ___________________________ |
1 Including short term investments (€20.4 million) and non-current financial instruments (€34.8 million) |
2 Cash and cash equivalents included proceeds relating to State-Guaranteed Loans |
3 Comparative relating to the six months ended June 30, 2021 have been restated to reflect the impact of the classification of Lumoxiti's activities as discontinued operations in 2021. |
View source version on businesswire.com:https://www.businesswire.com/news/home/20220914005962/en/
CONTACT: Investors
Innate Pharma
Henry Wheeler
Tel.: +33 (0)4 84 90 32 88
Henry.Wheeler@innate-pharma.frMedia Relations
NewCap
Arthur Rouille
Tel. : +33 (0)1 44 71 00 15
innate@newcap.eu
KEYWORD: FRANCE EUROPE
INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH PHARMACEUTICAL CLINICAL TRIALS ONCOLOGY
SOURCE: Innate Pharma SA
Copyright Business Wire 2022.
PUB: 09/15/2022 01:00 AM/DISC: 09/15/2022 01:03 AM
http://www.businesswire.com/news/home/20220914005962/en